Decreased serum SLC7A11 and GPX4 levels may reflect disease severity of acute ischaemic stroke.

IF 2.1 4区医学 Q3 MEDICAL LABORATORY TECHNOLOGY

Annals of Clinical Biochemistry Pub Date : 2024-12-04 DOI:10.1177/00045632241305927

Chuan-Peng Liu, Su Zheng, Ping Zhang, Guang-Hui Chen, Yuan-Yuan Zhang, Hui-Lin Sun, Li Peng

{"title":"Decreased serum SLC7A11 and GPX4 levels may reflect disease severity of acute ischaemic stroke.","authors":"Chuan-Peng Liu, Su Zheng, Ping Zhang, Guang-Hui Chen, Yuan-Yuan Zhang, Hui-Lin Sun, Li Peng","doi":"10.1177/00045632241305927","DOIUrl":null,"url":null,"abstract":"Objective: This study aimed to examine the levels of solute carrier family seven number 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) in the serum of patients with acute ischaemic stroke (AIS) and their relationship with disease severity.Methods: A total of 148 patients with AIS together with 148 healthy controls (HCs) were enrolled. The expression levels of SLC7A11 and GPX4 in serum were detected immediately as early as possible. Radiographic severity was detected by Alberta Stroke Program Early CT Score (ASPECTS). Disease severity was evaluated using modified Rankin Scale (mRS). High-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) expression levels were also measured. A correlation analysis was conducted to determine the relationship between the expression levels of SLC7A11 and GPX4 with the clinical severity of the disease and the levels of hs-CRP and MMP-9. Furthermore, receiver operating characteristic (ROC) curve analysis was utilized to assess the potential of SLC7A11 and GPX4 as diagnostic markers.Results: Compared to the HC group, the serum expression levels of SLC7A11 and GPX4 were significantly lower in the AIS group. Serum SLC7A11 levels were positively associated with serum GPX4 levels. The AIS group included 50 patients with mild neurological impairment, 52 with moderate neurological impairment, and 46 with severe neurological impairment. AIS patients with mild neurological impairment had drastically higher serum SLC7A11 and GPX4 levels compared with those with moderate neurological impairment. AIS patients with moderate neurological impairment showed significantly higher serum SLC7A11 and GPX4 concentrations compared with those with severe neurological impairment. ROC curve analysis demonstrated that both serum SLC7A11 and GPX4 may both act as potential indicators for evaluating of AIS disease severity. In addition, both serum SLC7A11 and GPX4 levels were positively correlated with ASPECTS. Both serum SLC7A11 and GPX4 levels were negatively associated with hs-CRP as well as MMP-9 levels. Serum SLC7A11 and GPX4 levels were significantly increased following comprehensive therapy.Conclusions: Decreased SLC7A11 and GPX4 levels may reflect disease severity of AIS.","PeriodicalId":8005,"journal":{"name":"Annals of Clinical Biochemistry","volume":" ","pages":"45632241305927"},"PeriodicalIF":2.1000,"publicationDate":"2024-12-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annals of Clinical Biochemistry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/00045632241305927","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICAL LABORATORY TECHNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: This study aimed to examine the levels of solute carrier family seven number 11 (SLC7A11) and glutathione peroxidase 4 (GPX4) in the serum of patients with acute ischaemic stroke (AIS) and their relationship with disease severity.

Methods: A total of 148 patients with AIS together with 148 healthy controls (HCs) were enrolled. The expression levels of SLC7A11 and GPX4 in serum were detected immediately as early as possible. Radiographic severity was detected by Alberta Stroke Program Early CT Score (ASPECTS). Disease severity was evaluated using modified Rankin Scale (mRS). High-sensitivity C-reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) expression levels were also measured. A correlation analysis was conducted to determine the relationship between the expression levels of SLC7A11 and GPX4 with the clinical severity of the disease and the levels of hs-CRP and MMP-9. Furthermore, receiver operating characteristic (ROC) curve analysis was utilized to assess the potential of SLC7A11 and GPX4 as diagnostic markers.

Results: Compared to the HC group, the serum expression levels of SLC7A11 and GPX4 were significantly lower in the AIS group. Serum SLC7A11 levels were positively associated with serum GPX4 levels. The AIS group included 50 patients with mild neurological impairment, 52 with moderate neurological impairment, and 46 with severe neurological impairment. AIS patients with mild neurological impairment had drastically higher serum SLC7A11 and GPX4 levels compared with those with moderate neurological impairment. AIS patients with moderate neurological impairment showed significantly higher serum SLC7A11 and GPX4 concentrations compared with those with severe neurological impairment. ROC curve analysis demonstrated that both serum SLC7A11 and GPX4 may both act as potential indicators for evaluating of AIS disease severity. In addition, both serum SLC7A11 and GPX4 levels were positively correlated with ASPECTS. Both serum SLC7A11 and GPX4 levels were negatively associated with hs-CRP as well as MMP-9 levels. Serum SLC7A11 and GPX4 levels were significantly increased following comprehensive therapy.

Conclusions: Decreased SLC7A11 and GPX4 levels may reflect disease severity of AIS.

查看原文本刊更多论文

血清SLC7A11和GPX4水平降低可能反映急性缺血性脑卒中的疾病严重程度。

目的：探讨急性缺血性脑卒中（AIS）患者血清溶质载体家族7号11 （SLC7A11）和谷胱甘肽过氧化物酶4 （GPX4）水平及其与病情严重程度的关系。方法：共纳入148例AIS患者和148例健康对照者。尽早检测血清中SLC7A11和GPX4的表达水平。放射学严重程度由阿尔伯塔卒中计划早期CT评分（方面）检测。采用改良Rankin量表（mRS）评估疾病严重程度。同时检测高敏c反应蛋白（hs-CRP）和基质金属蛋白酶-9 （MMP-9）的表达水平。通过相关分析确定SLC7A11、GPX4表达水平与临床疾病严重程度及hs-CRP、MMP-9水平的关系。此外，采用受试者工作特征（ROC）曲线分析来评估SLC7A11和GPX4作为诊断标志物的潜力。结果：与HC组相比，AIS组血清SLC7A11、GPX4表达水平明显降低。血清SLC7A11水平与血清GPX4水平呈正相关。AIS组包括50例轻度神经损伤患者，52例中度神经损伤患者，46例重度神经损伤患者。伴有轻度神经损伤的AIS患者血清SLC7A11和GPX4水平明显高于中度神经损伤患者。中度神经功能损害的AIS患者血清SLC7A11和GPX4浓度明显高于重度神经功能损害患者。ROC曲线分析显示血清SLC7A11和GPX4均可作为评价AIS疾病严重程度的潜在指标。血清SLC7A11和GPX4水平均与ASPECTS呈正相关。血清SLC7A11和GPX4水平与hs-CRP和MMP-9水平呈负相关。综合治疗后血清SLC7A11和GPX4水平明显升高。结论：SLC7A11和GPX4水平降低可能反映AIS的病情严重程度。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Annals of Clinical Biochemistry Biochemistry, Genetics and Molecular Biology-Clinical Biochemistry

CiteScore

5.20

自引率

4.50%

发文量

期刊介绍： Annals of Clinical Biochemistry is the fully peer reviewed international journal of the Association for Clinical Biochemistry and Laboratory Medicine. Annals of Clinical Biochemistry accepts papers that contribute to knowledge in all fields of laboratory medicine, especially those pertaining to the understanding, diagnosis and treatment of human disease. It publishes papers on clinical biochemistry, clinical audit, metabolic medicine, immunology, genetics, biotechnology, haematology, microbiology, computing and management where they have both biochemical and clinical relevance. Papers describing evaluation or implementation of commercial reagent kits or the performance of new analysers require substantial original information. Unless of exceptional interest and novelty, studies dealing with the redox status in various diseases are not generally considered within the journal''s scope. Studies documenting the association of single nucleotide polymorphisms (SNPs) with particular phenotypes will not normally be considered, given the greater strength of genome wide association studies (GWAS). Research undertaken in non-human animals will not be considered for publication in the Annals. Annals of Clinical Biochemistry is also the official journal of NVKC (de Nederlandse Vereniging voor Klinische Chemie) and JSCC (Japan Society of Clinical Chemistry).